Drug-resistant bacteria can infect anyone, anywhere. Nearly 1.3 million people die every year of drug-resistant infections. It’s why antibiotic resistance is one of the biggest threats to health in North America and globally.

Face the facts


people die of drug-resistant infections every year

1 in 5

cancer patients undergoing treatment is hospitalized due to infections


dollars in annual financial losses due to drug-resistant infections in the U.S. alone

Antibiotic resistance explained

The discovery of antibiotics transformed our world by making previously incurable illnesses treatable and allowing medical procedures such as surgery and chemotherapy to be performed safely. Millions of lives have been saved and our well-being radically improved.


But our time with these drugs is running out. Antibiotics have been used so extensively that many are losing their ability to stop bacteria, which can evolve to defeat these treatments. Because new antibiotics must be used carefully to slow the emergence of resistance, their development is not seen as profitable.


“The rise of drug-resistant bacteria is jeopardizing decades of progress and threatening our ability to prevent and treat infections that were once easy to treat. The Global Antibiotic Research and Development Partnership is an essential element of delivering the Global Action Plan on Antimicrobial Resistance.”

- Dr. Tedros Adhanom Ghebreyesus, WHO Director-General

We must fund the research and development of new antibiotics today and ensure access to these treatments for everyone who needs them, wherever they live.

Developing new treatments


Antibiotics are the backbone of modern medicine. They’ve saved hundreds of millions of lives and allowed medical procedures like operations and chemotherapy to be performed safely. But bacteria evolve to resist antibiotics so new drugs are needed. However, because new antibiotics are restricted to “last resort” cases to slow the emergence of resistance, they’re not seen as profitable. Most pharmaceutical companies have abandoned the research and development of these drugs.


The Global Antibiotic Research and Development Partnership (GARDP) is a global not-for-profit organization working to fix this broken market by bringing together the public, private, academic and civil society sectors to develop lifesaving and lifechanging treatments for drug-resistant bacterial infections. This includes groundbreaking research on the best use of antibiotics for newborns and children, supporting the late-stage development of a new treatment for drug-resistant gonorrhea, and collaborating on novel antibiotics for hospital-acquired infections with limited treatment options.

Providing solutions

Drug-resistant infections are responsible for nearly 1.3 million deaths a year. Babies and children are losing their lives to treatable diseases like sepsis. The spread of drug-resistant sexually transmitted infections has devastating consequences on reproductive health and heightens the risk of HIV transmission. One in ten hospital patients will contract a resistant infection and many are dying due to the lack of effective medicines.


GARDP is working to address this global health crisis by accelerating the development of treatments for drug-resistant infections, for every person who needs them.

Research and development stories

“Not only were patients battling with COVID, they then had to face a secondary infection, which could often not be treated because of antibiotic resistance.”

by Chelsea Kruger (medical doctor and researcher)

Load more

Take action now. Support our lifesaving and lifechanging work.